Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Must be 6 to less than 18 years of age at the time of randomization~* Plaque-type psoriasis history for at least 3 months.~Severe plaque-type psoriasis meeting all of the following three criteria:~* PASI score of 20 or greater,~* Investigator's Global Assessment (IGA) score of 4~* Total body surface area (BSA) affected of 10% or greater.~* Patient being regarded by the investigator to be a candidate for systemic therapy because of:~  1. inadequate control of symptoms with topical treatment, or~ 2. failure to respond to or tolerate previous systemic treatment and/or UV therapy~Exclusion criteria~* Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate) at randomization.~* Current drug-induced psoriasis.~* Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.~* Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy~* History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.~* History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.~* Pregnant or nursing (lactating) women.~* Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Secukinumab low dose (Type: EXPERIMENTAL): Secukinumab
- Secukinumab high dose (Type: EXPERIMENTAL): Secukinumab
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Etanercept Comparator (Type: ACTIVE_COMPARATOR): Etanercept

Based on this trial design, predict the completion outcome and termination type (if applicable).